Investor Stock List
Ranked #3,048 of 8,699 institutional investors

Decheng Capital LLC

Menlo Park, CA

$670M
US stock portfolio at live prices · today +$13.0M (+1.98%)
Market closed. Prices as of Nov 20, 9:11 AM ET
Value at quarter end (Q3 2026)
$685M
Change from Q2 2026
−$46.7M (−6.38%)
Positions
10 · 0 new, 2 sold out
Filed
Nov 13, 2026

Not counted in the ranking: none$2.4M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
CGON 77.9%NUVB 14.8%ACRS 2.11%LYEL 1.40%RCUS 1.00%
StockSharesValue, live% of portfoliovs Q2 2026
CGON CG Oncology, Inc.6,371,669$522M77.9%Unchanged
NUVB Nuvation Bio Inc.25,954,439$98.9M14.8%Unchanged
ACRS Aclaris Therapeutics, Inc.4,041,736$14.1M2.11%Unchanged
LYEL Lyell Immunopharma, Inc.692,050$9.4M1.40%Unchanged
RCUS Arcus Biosciences, Inc.425,079$6.7M1.00%Reduced −9%
UPB Upstream Bio, Inc.2,724,868$5.4M0.81%Unchanged
EQ Equillium, Inc.4,447,308$5.0M0.74%Unchanged
AARD Aardvark Therapeutics, Inc.3,917,299$3.9M0.58%Unchanged
ZNTL Zentalis Pharmaceuticals, Inc.1,323,327$1.8M0.27%Unchanged
PYXS Pyxis Oncology, Inc.326,810$549K<0.1%Unchanged

Sold out in Q3 2026

StockShares held at Q2 2026Worth today
RVMD Revolution Medicines, Inc.52,667$8.4M
TNGX Tango Therapeutics, Inc.20,000$454K